Myriad Genetics (MYGN) Sell-Off 'Seems Overdone' - Cowen
Tweet Send to a Friend
Cowen analyst Doug Schenkel weighed in on Myriad Genetics (NASDAQ: MYGN) and views the 15% sell-off as 'overdone'.The sell-off ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
